##  [Novartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients](/us-en/news/media-releases/novartis-kisqali-reports-longest-median-overall-survival-postmenopausal-hrher2-metastatic-breast-cancer-patients-0 "Novartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients") 

  Jun 02, 2021